Doubt about the size of any quick profit were raised today by the debut of the latest new issue, CKI Life Sciences, which opened with a 14% premium over the issue price, a modest gain by past Hong Kong standards. The gain in the shares owed more to the controlling interest of local tycoon Li Kashing than to any long-term expectations that it would be a biotechnology winner, warned sceptical commentators.